Recombinant Human CD74/DHLAG Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02464P-100UG
Human CD74 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human CD74/DHLAG Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02464P-100UG
Collections: Car-nk targets proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human CD74/DHLAG Protein is expressed from HEK293 with His tag at the N-Terminus.It contains Gln73-Met232. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | NP_004346.1 |
Target Symbol | CD74/DHLAG |
Synonyms | CD74; Ii; DHLAG; HLADG; Ia-GAMMA; p33; CLIP; INVG34; Ia-GAMMA ; II |
Species | Human |
Expression System | HEK293 |
Tag | N-His |
Expression Range | Gln73-Met232 |
Mol. Weight | The protein has a predicted MW of 19.1 kDa. Due to glycosylation, the protein migrates to 30-40 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human CD74 at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Anti-CD74 Antibody, hFc Tag with the EC50 of 8.9ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | CD74 (invariant MHC class II) regulates protein trafficking and is a receptor for macrophage migration inhibitory factor (MIF) and d-dopachrome tautomerase (d-DT/MIF-2). CD74 expression is increased in tubular cells and/or glomerular podocytes and parietal cells in human metabolic nephropathies, polycystic kidney disease, graft rejection and kidney cancer and in experimental diabetic nephropathy and glomerulonephritis. |